- Home
- MYNZ vs ICU Comparison
MYNZ vs ICU Comparison
Compare MYNZ & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- ICU
- Stock Information
- Founded
- MYNZ 2021
- ICU 2018
- Country
- MYNZ Germany
- ICU United States
- Employees
- MYNZ N/A
- ICU N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- ICU Health Care
- Exchange
- MYNZ Nasdaq
- ICU Nasdaq
- Market Cap
- MYNZ 10.5M
- ICU 10.4M
- IPO Year
- MYNZ 2021
- ICU N/A
- Fundamental
- Price
- MYNZ $3.44
- ICU $1.35
- Analyst Decision
- MYNZ Buy
- ICU
- Analyst Count
- MYNZ 3
- ICU 0
- Target Price
- MYNZ $14.00
- ICU N/A
- AVG Volume (30 Days)
- MYNZ 177.3K
- ICU 228.5K
- Earning Date
- MYNZ 04-15-2025
- ICU 03-27-2025
- Dividend Yield
- MYNZ N/A
- ICU N/A
- EPS Growth
- MYNZ N/A
- ICU N/A
- EPS
- MYNZ N/A
- ICU N/A
- Revenue
- MYNZ $893,991.00
- ICU $135,000.00
- Revenue This Year
- MYNZ $20.94
- ICU N/A
- Revenue Next Year
- MYNZ $18.01
- ICU N/A
- P/E Ratio
- MYNZ N/A
- ICU N/A
- Revenue Growth
- MYNZ N/A
- ICU N/A
- 52 Week Low
- MYNZ $0.18
- ICU $1.33
- 52 Week High
- MYNZ $8.20
- ICU $20.00
- Technical
- Relative Strength Index (RSI)
- MYNZ 37.70
- ICU 32.31
- Support Level
- MYNZ $2.72
- ICU $1.56
- Resistance Level
- MYNZ $5.34
- ICU $2.57
- Average True Range (ATR)
- MYNZ 0.55
- ICU 0.23
- MACD
- MYNZ -0.12
- ICU -0.09
- Stochastic Oscillator
- MYNZ 27.48
- ICU 1.61
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.